South Wales, Nov. 6 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "NUCLEOME" on Feb. 11, 2025. The details about the trademark application no. UK00004158727 published in the journal no. 2026/045 (Nov. 6).
With Mathys & Squire LLP as representative, Nucleome Therapeutics Limited filed the trademark application for the below mentioned good(s)/service(s).
Class 1 : Reagents and kits for research, industry and diagnostic purposes [not for medical or veterinary use]; Reagents and kits for medical research; Biological preparations for use in research, industry and science; human cells and isogenic cell lines for research or scientific purposes [not for medical or veterinary use].
Class 5 : Pharmaceuticals; pharmaceutical preparations, substances, and compounds for medical use; therapeutic drugs and agents; biotechnology preparations, substances and compounds for medical use; cells for medical use; gene therapy products for medical use; reagents for use in medical genetic testing; reagents and testing kits for medical use; diagnostic reagents and kits for medical use.
Class 9 : Computer software; computer platform software; computer database software; computer software for data analysis and reporting; computer software for the sequencing, annotation, analysis, interpretation and reporting of genome data; computer software for potential patient identification, potential patient stratification and medical diagnosis; computer software for drug discovery and research; computer software for research and medical purposes; computer software for analysis of data relating to pharmaceutical development; computer databases; computer database servers; computer software for database management; computer software for creating searchable databases of information and data.
Class 42 : Research and development services; scientific research and development services; biotechnology research and development services; pharmaceutical research and development services; drug discovery; pharmaceutical drug development; research and development services in the field of genomics; structural and functional analysis of genomes; research and development services in the field of bioinformatics; research and development services in the field of personalised medicine; research and development services in the field of precision medicine; research and development services in the field of stratified medicine; research and development in the field of drug discovery; research and development in the field of drug target discovery; research and development services in the field of clinical trial design; research and development services in the field of medical diagnostics; research and development of pharmaceuticals and compounds; research and development of pharmaceutical preparations and medicines; research and development of medicines; medical research and development services; research related to genomics, bioinformatics, personalised medicine, precision medicine, drug discovery; design and development of databases; design and development of computer software; design and development of computer databases; database design and development services; computer database design and development services; design and development of computer software for services in the field of pharmaceuticals, clinical trials, personalised medicine and genetics; design and development of computer database for services in the field of pharmaceuticals, clinical trials, personalised medicine and genetics; genome interpretation services; providing computer software and databases as a service for genome sequencing, annotation, interpretation and reporting; providing software and databases as a service for drug discovery and research; providing software and databases as a service for potential patient identification, potential patient stratification or medical diagnosis; providing software and databases as a service for research and medical purposes; information, advisory and consultancy services in relation to all of the aforesaid; cell-line engineering services; gene-editing services; consultancy, advisory and/or information services relating to or connected with the aforementioned services.
Class 44 : Analysis of data for medical and health purposes; providing information, advice and data relating to genetics and pharmaceuticals for medical and health purposes; pharmaceutical services; medical and health services relating to DNA, genetics and genetic testing; providing a computer database featuring information regarding health; consultancy, advisory and/or information services relating to or connected with the aforementioned services.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004158727
Disclaimer: Curated by HT Syndication.
